Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
101.81
223
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Sichuan Biokin Pharmaceutical Co Ltd
Total Current Assets
Sichuan Biokin Pharmaceutical Co Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Current Assets
¥775.8m
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Current Assets
¥28.9B
|
CAGR 3-Years
19%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Total Current Assets
¥15.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Current Assets
¥34.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Current Assets
¥36.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
12%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Total Current Assets
¥2.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
Sichuan Biokin Pharmaceutical Co Ltd
Glance View
Sichuan Biokin Pharmaceutical Co., Ltd. is an emerging player in the pharmaceutical landscape of China, specializing in the research, development, and manufacturing of innovative biopharmaceuticals. Founded in 2003, the company has established itself as a key contributor to the advancement of biotechnology, focusing on high-quality biosimilars and innovative drugs that address unmet medical needs. With a commitment to rigorous R&D and a collaborative approach to partnerships, including collaborations with internationally recognized institutions, Biokin is poised to enhance its product pipeline significantly. The company’s strong emphasis on biologic therapies positions it favorably within the industry, tapping into the growing global demand for effective, complex therapeutics that target various chronic and rare diseases. For investors, Sichuan Biokin represents a compelling opportunity due to its strategic positioning in a rapidly growing market segment that benefits from favorable governmental support for biotechnology innovation. As China's healthcare sector continues to expand, driven by an aging population and increasing investment in healthcare technology, Biokin’s strong foothold in biosimilars and the growing pipeline of innovative therapies suggest considerable future growth potential. Additionally, the company’s focus on adhering to international quality standards and gaining regulatory approvals could open doors to expand its market reach beyond China, enhancing long-term shareholder value. With a solid foundation in biotechnology and an ambitious vision for expansion, Sichuan Biokin is a company worth watching for investors looking to capitalize on the evolving pharmaceutical industry.
See Also
What is Sichuan Biokin Pharmaceutical Co Ltd's Total Current Assets?
Total Current Assets
775.8m
CNY
Based on the financial report for Dec 31, 2023, Sichuan Biokin Pharmaceutical Co Ltd's Total Current Assets amounts to 775.8m CNY.
What is Sichuan Biokin Pharmaceutical Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 3Y
11%
Over the last year, the Total Current Assets growth was -46%. The average annual Total Current Assets growth rates for Sichuan Biokin Pharmaceutical Co Ltd have been 11% over the past three years .
You don't have any saved screeners yet
